Asthma (Diagnosis)WCT-ASTHMANCT07764042
Effects of Wet Cupping Therapy in Patients With Asthma
A study testing Wet Cupping Therapy in people with Asthma (Diagnosis), run by Medipol University at 1 site in Turkey (Türkiye).
Trial summary
This study evaluated the effects of wet cupping therapy on immune modulation, pulmonary function, and quality of life in adults with asthma. A total of 52 participants aged 30 to 55 years were allocated to either a control group or a wet cupping therapy group. Read more about this study
- Who is it for?
- Ages 30 to 55 years
- Conditions the study is for
- Asthma (Diagnosis)
- What is being tested?
- Wet Cupping Therapy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 52 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 19 May 2025to 13 Jan 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 55 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Adults aged 30 to 55 years.
- Clinically diagnosed with asthma.
- Asthma diagnosis established at least 6 months before enrollment.
- No wet cupping therapy within the previous 2 months.
- No herbal supplementation affecting asthma within the previous 2 months.
- Able to cooperate with spirometry testing.
Who cannot join
- Presence of another chronic disease.
- Hospitalization during the study period.
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Medipol Mega University Hospital
Istanbul, Istanbul
About this study
Official title: Investigation of the Effects of Wet Cupping Therapy on Immune Modulation, Pulmonary Function, and Quality of Life in Patients With Asthma
This study evaluated the effects of wet cupping therapy on immune modulation, pulmonary function, and quality of life in adults with asthma. A total of 52 participants aged 30 to 55 years were allocated to either a control group or a wet cupping therapy group. Participants in the wet cupping therapy group received two sessions of wet cupping therapy, at baseline and one month later. Participants in both groups underwent clinical assessments at baseline and at two months. Pulmonary function, asthma-related quality of life, asthma control, dyspnea, fatigue, anxiety, and depression were assessed in both groups. Selected inflammatory markers were assessed only in the wet cupping therapy group.
- Conditions
- Asthma (Diagnosis)
- Being tested
- Wet Cupping Therapy
- Keywords
- Wet Cupping Therapy, Asthma, Pulmonary Function, Quality of Life, Immune Modulation, Asthma Control
- Medical subject headings
- Asthma, Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Wet Cupping TherapyProcedure or surgery
Wet cupping therapy was administered in two sessions at one-month intervals during the two-month study period. The procedure was performed at predefined anatomical points, including DU14, bilateral UB42, BL13, UB46. Negative-pressure cups were initially applied to the selected areas. After removal of the cups, superficial skin incisions were made using a sterile disposable No. 11 scalpel, followed by a second application of negative pressure for blood collection. Each session was planned to last approximately 30 minutes. The procedure was performed by a physician certified in wet cupping therapy.
| Study group | Role | What they receive |
|---|---|---|
| Control Group | No intervention | Participants in the control group underwent pulmonary function testing at baseline and at two months and completed the study assessment scales at baseline and at the end of the study. |
| Wet Cupping Therapy Group | Experimental | Participants received wet cupping therapy twice during the two-month study period, with the first session at baseline and the second session one month later. Pulmonary function testing and study assessments were performed at baseline and at two months. Receives: Procedure: Wet Cupping Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in FVC From Baseline to 2 Months
Forced vital capacity (FVC) was assessed by spirometry. Change from baseline to 2 months was evaluated.
Measured: Baseline and 2 months
Change in Asthma Quality of Life Questionnaire Score From Baseline to 2 Months
Asthma-related quality of life was assessed using the Asthma Quality of Life Questionnaire (AQLQ). Higher scores indicate better asthma-related quality of life.
Measured: Baseline and 2 months
Change in COPD and Asthma Fatigue Scale Score From Baseline to 2 Months
Fatigue was assessed using the COPD and Asthma Fatigue Scale. Higher scores indicate greater fatigue severity.
Measured: Baseline and 2 months
Change in FEV1 From Baseline to 2 Months
Forced expiratory volume in 1 second (FEV1) was assessed by spirometry. Change from baseline to 2 months was evaluated.
Measured: Baseline and 2 months
Change in FEV1/FVC Ratio From Baseline to 2 Months
The FEV1/FVC ratio was assessed by spirometry. Change from baseline to 2 months was evaluated.
Measured: Baseline and 2 months
Change in PEF From Baseline to 2 Months
Peak expiratory flow (PEF) was assessed by spirometry. Change from baseline to 2 months was evaluated.
Measured: Baseline and 2 months
Change in Systemic Immune-Inflammation Index (SII) in the Wet Cupping Therapy Group From Baseline to 2 Months
The Systemic Immune-Inflammation Index (SII) was calculated from peripheral blood cell counts using platelet, neutrophil, and lymphocyte values. SII was assessed only in the wet cupping therapy group. The change in SII from baseline to 2 months was evaluated as an indicator of systemic immune-inflammatory status.
Measured: Baseline and 2 months
Change in Systemic Inflammation Response Index (SIRI) in the Wet Cupping Therapy Group From Baseline to 2 Months
The Systemic Inflammation Response Index (SIRI) was calculated from peripheral blood cell counts using monocyte, neutrophil, and lymphocyte values. SIRI was assessed only in the wet cupping therapy group. The change in SIRI from baseline to 2 months was evaluated as an indicator of systemic inflammatory status.
Measured: Baseline and 2 months
Secondary outcomes (4)
Change in Asthma Control Test Score From Baseline to 2 Months
Asthma control was assessed using the Asthma Control Test (ACT). The ACT is a 5-item questionnaire with a total score ranging from 5 to 25, with higher scores indicating better asthma control.
Measured: Baseline and 2 months
Change in Modified Medical Research Council Dyspnea Scale Score From Baseline to 2 Months
Dyspnea was assessed using the modified Medical Research Council (mMRC) dyspnea scale. The scale ranges from 0 to 4, with higher scores indicating greater severity of breathlessness.
Measured: Baseline and 2 months
Change in Hospital Anxiety and Depression Scale Scores From Baseline to 2 Months
Anxiety and depressive symptoms were assessed using the Hospital Anxiety and Depression Scale (HADS). The HADS consists of 14 items, including 7 anxiety items and 7 depression items, each scored from 0 to 3. Higher subscale scores indicate greater anxiety or depressive symptoms.
Measured: Baseline and 2 months
Change in Eosinophil Level in the Wet Cupping Therapy Group From Baseline to 2 Months
Peripheral blood eosinophil levels were assessed only in the wet cupping therapy group. Within-group changes from baseline to 2 months were evaluated.
Measured: Baseline and 2 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Aug 2026
- Study start19 May 2025
- Primary completion13 Jan 2026
- Study completion13 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Asthma (Diagnosis)Studies of the same condition, open and under way.
- More trials run by Medipol UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants were assigned to one of two parallel groups: a control group that did not receive wet cupping therapy and an intervention group that received wet cupping therapy.
- Masking
- None (open label)
- Enrolment
- 52 participants (actual)
Sponsor and investigators
- Lead sponsor
- Medipol University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, TUBA ÖZDEMİR, Medipol University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07764042
- Sponsor's protocol ID
- IMU-WCT-ASTHMA-2025
- Other IDs
- 2025-10
- Acronym
- WCT-ASTHMA
- Status last verified
- Aug 2026
- First submitted
- 9 Aug 2026
- Last updated
- 13 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of the Effects of Wet Cupping Therapy on Immune Modulation, Pulmonary Function, and Quality of Life in Patients With Asthma
- ClinicalTrials.gov ID
- NCT07764042
- Acronym / sponsor ID
- WCT-ASTHMA / IMU-WCT-ASTHMA-2025
- Conditions
- Asthma (Diagnosis)
- Keywords
- Wet Cupping Therapy, Asthma, Pulmonary Function, Quality of Life, Immune Modulation, Asthma Control
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 52 participants (actual)
- Lead sponsor
- Medipol UniversityUniversity, hospital or other
- Study start
- 19 May 2025 (actual)
- Primary completion
- 13 Jan 2026 (actual)
- Study completion
- 13 Jan 2026 (actual)
- First posted
- 13 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluated the effects of wet cupping therapy on immune modulation, pulmonary function, and quality of life in adults with asthma. A total of 52 participants aged 30 to 55 years were allocated to either a control group or a wet cupping therapy group. Participants in the wet cupping therapy group received two sessions of wet cupping therapy, at baseline and one month later. Participants in both groups underwent clinical assessments at baseline and at two months. Pulmonary function, asthma-related quality of life, asthma control, dyspnea, fatigue, anxiety, and depression were assessed in both groups. Selected inflammatory markers were assessed only in the wet cupping therapy group.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Participants were assigned to one of two parallel groups: a control group that did not receive wet cupping therapy and an intervention group that received wet cupping therapy.
| Arm | Type | Receives |
|---|---|---|
| Control Group | No intervention | –Participants in the control group underwent pulmonary function testing at baseline and at two months and completed the study assessment scales at baseline and at the end of the study. |
| Wet Cupping Therapy Group | Experimental | Procedure: Wet Cupping TherapyParticipants received wet cupping therapy twice during the two-month study period, with the first session at baseline and the second session one month later. Pulmonary function testing and study assessments were performed at baseline and at two months. |
Who may qualify
- Ages
- 30 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Adults aged 30 to 55 years.
- Clinically diagnosed with asthma.
- Asthma diagnosis established at least 6 months before enrollment.
- No wet cupping therapy within the previous 2 months.
- No herbal supplementation affecting asthma within the previous 2 months.
Key exclusion criteria (2 listed)
- Presence of another chronic disease.
- Hospitalization during the study period.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Wet Cupping TherapyWet cupping therapy was administered in two sessions at one-month intervals during the two-month study period. The procedure was performed at predefined anatomical points, including DU14, bilateral UB42, BL13, UB46. Negative-pressure cups were initially applied to the selected areas. After removal of the cups, superficial skin incisions were made using a sterile disposable No. 11 scalpel, followed by a second application of negative pressure for blood collection. Each session was planned to last approximately 30 minutes. The procedure was performed by a physician certified in wet cupping therapy. | Procedure or surgery | Wet Cupping Therapy Group |
Primary outcome
Change in FVC From Baseline to 2 Months
Time frame: Baseline and 2 months
Forced vital capacity (FVC) was assessed by spirometry. Change from baseline to 2 months was evaluated.
Change in Asthma Quality of Life Questionnaire Score From Baseline to 2 Months
Time frame: Baseline and 2 months
Asthma-related quality of life was assessed using the Asthma Quality of Life Questionnaire (AQLQ). Higher scores indicate better asthma-related quality of life.
Change in COPD and Asthma Fatigue Scale Score From Baseline to 2 Months
Time frame: Baseline and 2 months
Fatigue was assessed using the COPD and Asthma Fatigue Scale. Higher scores indicate greater fatigue severity.
Change in FEV1 From Baseline to 2 Months
Time frame: Baseline and 2 months
Forced expiratory volume in 1 second (FEV1) was assessed by spirometry. Change from baseline to 2 months was evaluated.
Change in FEV1/FVC Ratio From Baseline to 2 Months
Time frame: Baseline and 2 months
The FEV1/FVC ratio was assessed by spirometry. Change from baseline to 2 months was evaluated.
Change in PEF From Baseline to 2 Months
Time frame: Baseline and 2 months
Peak expiratory flow (PEF) was assessed by spirometry. Change from baseline to 2 months was evaluated.
Change in Systemic Immune-Inflammation Index (SII) in the Wet Cupping Therapy Group From Baseline to 2 Months
Time frame: Baseline and 2 months
The Systemic Immune-Inflammation Index (SII) was calculated from peripheral blood cell counts using platelet, neutrophil, and lymphocyte values. SII was assessed only in the wet cupping therapy group. The change in SII from baseline to 2 months was evaluated as an indicator of systemic immune-inflammatory status.
Change in Systemic Inflammation Response Index (SIRI) in the Wet Cupping Therapy Group From Baseline to 2 Months
Time frame: Baseline and 2 months
The Systemic Inflammation Response Index (SIRI) was calculated from peripheral blood cell counts using monocyte, neutrophil, and lymphocyte values. SIRI was assessed only in the wet cupping therapy group. The change in SIRI from baseline to 2 months was evaluated as an indicator of systemic inflammatory status.
4 secondary outcomes
Change in Asthma Control Test Score From Baseline to 2 Months
Time frame: Baseline and 2 months
Change in Modified Medical Research Council Dyspnea Scale Score From Baseline to 2 Months
Time frame: Baseline and 2 months
Change in Hospital Anxiety and Depression Scale Scores From Baseline to 2 Months
Time frame: Baseline and 2 months
Change in Eosinophil Level in the Wet Cupping Therapy Group From Baseline to 2 Months
Time frame: Baseline and 2 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Asthma (Diagnosis)
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
RecruitingPhase 1
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
Asthma, Mild Asthma
RecruitingPhase 3
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
Asthma Control
Active, not recruitingPhase 2/3
Local Antibiotic Delivery for Community Acquired Pneumonia
Community Acquired Pneumonia (CAP)
RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Wet Cupping Therapy in people with Asthma (Diagnosis), run by Medipol University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in FVC From Baseline to 2 Months (time frame: Baseline and 2 months). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2026.